<SEC-DOCUMENT>0001935979-22-000009.txt : 20221109
<SEC-HEADER>0001935979-22-000009.hdr.sgml : 20221109
<ACCEPTANCE-DATETIME>20221109160539
ACCESSION NUMBER:		0001935979-22-000009
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20221109
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221109
DATE AS OF CHANGE:		20221109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Biohaven Ltd.
		CENTRAL INDEX KEY:			0001935979
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41477
		FILM NUMBER:		221372507

	BUSINESS ADDRESS:	
		STREET 1:		215 CHURCH STREET
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
		BUSINESS PHONE:		203-404-0410

	MAIL ADDRESS:	
		STREET 1:		215 CHURCH STREET
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Biohaven Research Ltd.
		DATE OF NAME CHANGE:	20220629
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bhvn-20221109.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:21e66218-f164-470d-965c-dd4feffa9b8b,g:5b8cb720-4ac7-485e-ac76-aba17a964af5,d:f9f655b3d84942fba1fc4076d8a3e17a--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bhvn-20221109</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV80L2ZyYWc6Y2MzYTYyOTc5MTJhNDQ2MDk2MGRmOGM3ZjMyYmMzYTAvdGFibGU6YzQ5NWI4NTg1ZWY1NDVmMzhmYzdkYmUzZmMzMmU1ODAvdGFibGVyYW5nZTpjNDk1Yjg1ODVlZjU0NWYzOGZjN2RiZTNmYzMyZTU4MF8wLTEtMS0xLTIyNzIzNA_625b1c92-ae7d-49d6-a061-6ab5d65f5727">0001935979</ix:nonNumeric><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV80L2ZyYWc6Y2MzYTYyOTc5MTJhNDQ2MDk2MGRmOGM3ZjMyYmMzYTAvdGFibGU6YzQ5NWI4NTg1ZWY1NDVmMzhmYzdkYmUzZmMzMmU1ODAvdGFibGVyYW5nZTpjNDk1Yjg1ODVlZjU0NWYzOGZjN2RiZTNmYzMyZTU4MF8xLTEtMS0xLTIyNzIzNA_2431fe87-b528-4457-bae1-08557a7bdba3">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bhvn-20221109.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001935979</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-09</xbrli:startDate><xbrli:endDate>2022-11-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if9f655b3d84942fba1fc4076d8a3e17a_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzY0_069aea85-fcee-4ba8-814d-ee0a28680d5c">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8yMjE_f79aa8f5-bef9-43db-b019-937a7c2df2c1">November&#160;9, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzY1_295b862d-421f-44a6-9e8a-d959d2a99a79">Biohaven Ltd.</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGFibGU6OWIwNTNlZjAzNDI0NGJlOTk2MzMwOGQ3MDU5MWMzMjcvdGFibGVyYW5nZTo5YjA1M2VmMDM0MjQ0YmU5OTYzMzA4ZDcwNTkxYzMyN18wLTAtMS0xLTIyNzIzNA_b8d078e8-0603-4e10-a4f5-087fb4dbead1">British Virgin Islands</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGFibGU6OWIwNTNlZjAzNDI0NGJlOTk2MzMwOGQ3MDU5MWMzMjcvdGFibGVyYW5nZTo5YjA1M2VmMDM0MjQ0YmU5OTYzMzA4ZDcwNTkxYzMyN18wLTEtMS0xLTIyNzIzNA_d44b040e-b78a-48cc-aa95-d95c2cb21561">001-41477</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Not applicable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzU3_a0854a5c-fd97-4311-a985-fd8e9372c979">c/o Biohaven Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzYx_2597c8f8-71f0-4ec2-865c-3ce26cabe7fa">215 Church Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzU4_70c400a7-b02e-4093-b3ae-315d2c078e5d">New Haven</ix:nonNumeric>, <ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzU5_330e3c20-815d-4da6-b2fd-914fb074b333">Connecticut</ix:nonNumeric> <ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzU0_c99c2a21-d9d2-4b6a-b669-13990c1d4adb">06510</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzY2_e55bb340-b8b6-4e2e-b7e4-c7ecb5c30c48">203</ix:nonNumeric>) <ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzY3_9322b401-a552-4a99-b17a-ec6c877b1104">404-0410</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzYy_2dde2e71-5926-48d4-bf07-630b42284f44">&#9744;</ix:nonNumeric>&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzU1_dd3b3028-33b9-40b1-b637-01b98052c6b4">&#9744;</ix:nonNumeric>&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzU2_f71c8795-3b66-47f9-a5b9-7a1883ee458a">&#9744;</ix:nonNumeric>&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzYw_4bbeb105-4d72-4da4-bd31-90239938d8df">&#9744;</ix:nonNumeric>&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:37.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.649%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading symbol</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGFibGU6N2FiMzljMWExMzY2NGE5OGIxM2Y2NTMyYjM4ZDg0ODYvdGFibGVyYW5nZTo3YWIzOWMxYTEzNjY0YTk4YjEzZjY1MzJiMzhkODQ4Nl8xLTAtMS0xLTIyNzIzNA_f0d8adcc-254d-44ce-a008-e73a9d58f450">Common Shares, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGFibGU6N2FiMzljMWExMzY2NGE5OGIxM2Y2NTMyYjM4ZDg0ODYvdGFibGVyYW5nZTo3YWIzOWMxYTEzNjY0YTk4YjEzZjY1MzJiMzhkODQ4Nl8xLTEtMS0xLTIyNzIzNA_85ec11f3-7de2-4dd5-a24c-d6a84a3be816">BHVN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGFibGU6N2FiMzljMWExMzY2NGE5OGIxM2Y2NTMyYjM4ZDg0ODYvdGFibGVyYW5nZTo3YWIzOWMxYTEzNjY0YTk4YjEzZjY1MzJiMzhkODQ4Nl8xLTItMS0xLTIyNzIzNA_b2e8f358-b449-4c8b-a31d-3b1539fcc3fa">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzYz_a106accc-6148-4918-a033-10dd42cf8175">&#9746;</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xMDk5NTExNjI5NTg0_d25d9b8b-6dee-41cf-a2c9-863e7eb6b18e">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if9f655b3d84942fba1fc4076d8a3e17a_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;9, 2022, Biohaven Ltd. (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registrant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) issued a press release announcing its financial results for the third quarter ended September 30, 2022. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant&#8217;s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="if9f655b3d84942fba1fc4076d8a3e17a_10"></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">(d) Exhibits </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:19.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.857%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q3bhvnltdearningsprex.htm">Press Release, dated  November </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q3bhvnltdearningsprex.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q3bhvnltdearningsprex.htm">, 2022, "Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q3bhvnltdearningsprex.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q3bhvnltdearningsprex.htm">"</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page of this Current Report on Form 8-K formatted as Inline XBRL.</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;The XBRL instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2</span></div></div></div><div id="if9f655b3d84942fba1fc4076d8a3e17a_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date: November&#160;9, 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:139%">     </span></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.038%"><tr><td style="width:1.0%"></td><td style="width:14.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Biohaven Ltd.</span></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Matthew Buten</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew Buten</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="text-align:right"><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a2022q3bhvnltdearningsprex.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib7678ec1110f4751ac642666e16a5cf1_1"></div><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><font><br></font></div><div id="ib7678ec1110f4751ac642666e16a5cf1_4"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOHAVEN LTD. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND REPORTS RECENT BUSINESS DEVELOPMENTS</font></div><div><font><br></font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.5pt">Biohaven Ltd. launched post-closing of the Biohaven Pharmaceutical Holding Company Ltd. sale to Pfizer on October 4, 2022, and completed a public offering of 28,750,000 Biohaven Ltd. common shares at a price of $10.50 per share on October 25, 2022, with a total initial capitalization and net cash proceeds from offering of approximately $541 million, and no debt. </font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Advancing multiple late-stage clinical programs including innovative drug candidates targeting Kv7 modulation for epilepsy and neuropsychiatric disorders, glutamate modulation in Obsessive-Compulsive Disorder (OCD) and spinocerebellar ataxia (SCA), and myostatin in spinal muscular atrophy (SMA).                                                                                                    </font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.5pt">Key industry executives added to leadership team, including&#58; </font></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Bruce Car, Ph.D. as Chief Scientific Officer&#59; </font></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Irfan Qureshi, M.D. as Chief Medical Officer, and </font></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Tanya Fischer, M.D., Ph.D. as Chief Development Officer and Head of Translational Medicine. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">NEW HAVEN, Conn., November&#160;9, 2022 &#47;PRNewswire&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#8211; Biohaven Ltd. (NYSE&#58; BHVN) (&#34;Biohaven&#34; or the &#34;Company&#34;), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating neurological and neuropsychiatric diseases, including rare disorders, today reported financial results for the third quarter ended September 30, 2022, and provided a review of recent accomplishments and anticipated upcoming milestones. The reported financial results present, on a historical basis, the combined assets, liabilities, expenses and cash flows directly attributable to the Company, which have been prepared from Biohaven Pharmaceutical Holding Company Ltd., the former parent, consolidated financial statements and accounting records, and are presented on a stand-alone basis as if the operations had been conducted independently from the former parent.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, &#34;Just weeks after launching in October as a new publicly traded company and separate independent entity as part of the merger agreement with Pfizer, we continued to advance our late stage clinical development programs and substantially enhanced our resources by raising gross proceeds of approximately $301.9 million in a public financing that drew support from a breadth of longstanding and new Biohaven investors. We are well positioned with an outstanding drug development team, a deep late-stage pipeline and a strong capital position to favorably position us to accelerate development across our portfolio.&#8221;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Dr. Coric continued, &#34;Our Kv7 platform, with its vast potential to address epilepsy and neuropsychiatric indications, is being prioritized by the team with the goal of at least one Phase 2&#47;3 study start in 2023. We also continue to make progress with our Phase 3 study evaluating taldefgrobep alfa in patients with spinal muscular atrophy, as well as with our Phase 3 study evaluating troriluzole in patients with OCD. Finally, our discovery efforts remain a key pillar of our pipeline formation strategy&#59; with IND-enabling studies underway across several programs, we expect to provide updates on programs like TRPM3, a potential breakthrough, non-opioid treatment option for pain, and other earlier stage protein degrader programs in the coming months and years. Our unwavering commitment to patients continues propelling us forward and we cannot wait to deliver additional therapeutic breakthrough medicines to drive outcomes for patients, shareholders and employees.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Third Quarter and Recent Business Highlights&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Company launch </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On October 3, 2022, Biohaven Ltd. began operating as a separate independent entity in connection with the merger agreement entered into with Pfizer Inc. in May 2022. As of October 4, 2022, Biohaven Ltd. commenced regular way trading under the symbol &#34;BHVN&#34; on the New York Stock Exchange as an independent, publicly traded company focused on delivering innovative life-changing treatments for neurological and neuropsychiatric diseases, including rare disorders, and leveraging its proven drug development capabilities and proprietary technology platforms to advance a pipeline of best-in-class therapies. The Company, led by Vlad Coric, M.D. as Chairman and Chief Executive Officer, launched with approximately $257.8 million in cash and no debt.</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Public offering </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">- On October 25, 2022, the Company closed its previously announced underwritten public offering of 28,750,000 of its common shares, which includes the full exercise of the underwriters' option to purchase 3,750,000 additional shares, at the public offering price of $10.50 per share. The gross proceeds raised in the offering, before deducting underwriting discounts and estimated expenses of the offering payable by the Company, were approximately $301.9 million. As of November&#160;7, 2022, we had 68,160,979 common shares, without par value per share, outstanding.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Advanced Phase 1 studies for BHV-7000 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">- As previously reported, in the second quarter of 2022, the Company's Clinical Trial Application for BHV-7000 was approved by Health Canada, and the Company subsequently began clinical development. BHV-7000, the lead asset from the Kv7 platform, is an activator of Kv7.2&#47;Kv7.3, a key ion channel involved in neuronal signaling and in regulating the hyperexcitable state in epilepsy. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Advanced development of extracellular target degrader platform technology (MoDEs&#8482;) for therapies across a variety of diseases including neuroscience, immunology and oncology </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">- In October, Biohaven announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, infectious and autoimmune diseases. Biohaven made further innovations in this ground-breaking technology with new patent applications covering additional targets and functionality.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Operationalized fully-equipped Biohaven Cambridge laboratory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> - In October, the Company expanded its footprint to include new laboratory space in Cambridge, Massachusetts.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Commenced enrollment in Phase 3 SMA study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> - In July, the Company commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of taldefgrobep alfa in SMA. Taldefgrobep targets myostatin, a natural protein that limits skeletal muscle growth, through two mechanisms&#58; lowering myostatin directly and blocking key downstream signaling mechanisms. The Company expects to enroll approximately 180 patients in this randomized, double-blind, placebo-controlled global trial.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Global Coalition for Adaptive Research (GCAR) commenced enrollment in Glioblastoma Adaptive Global Innovative Learning Environment (GBM Agile) Phase 2-3 adaptive platform trial for patients with glioblastoma </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- In July, GCAR announced the activation of Biohaven's troriluzole in GBM AGILE, a patient-centered, adaptive platform trial for registration that tests multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (GBM). GBM AGILE is an international, innovative platform trial designed to more rapidly identify and confirm effective therapies for patients with glioblastoma through response adaptive randomization. The new interventions are opening first at Henry Ford Health Cancer in Detroit under Henry Ford site Principal Investigator Dr. Tom Mikkelsen and will subsequently open at more than 40 trial sites across the United States with additional global sites to follow.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;text-decoration:underline">Upcoming Milestones&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Biohaven is progressing its product candidates through clinical programs in a number of common and rare disorders. The Company expects to reach significant pipeline milestones in the coming periods. Biohaven expects to&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:14.15pt">Complete Phase 1 studies of BHV-7000 in the first half of 2023&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> If the Phase 1 studies are successfully completed, Biohaven expects to initiate at least one pivotal trial in patients with epilepsy in the second half of 2023. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Complete enrollment in Phase 3 study of troriluzole in OCD in 2023&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Two Phase 3 randomized, double-blind, placebo-controlled studies are expected to enroll approximately 1,300 patients across nearly 200 global study sites. The Company anticipates completing enrollment in 2023.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:14.15pt">Provide an update on troriluzole in SCA&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> The Company had previously reported top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of its investigational therapy, troriluzole, in </font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">patients with SCA in May of 2022. While the primary endpoint, change from baseline to Week 48 on the modified functional Scale for the Assessment and Rating of Ataxia did not reach statistical significance in the overall SCA population, as there was less than expected disease progression over the course of the study, post hoc analysis of efficacy measures by genotype suggested a treatment effect in patients with the SCA Type 3 (SCA3) genotype, which represents the most common form of SCA and accounted for 41 percent of the study population. The Company intends to interact with the FDA and&#47;or EMA in the first half of 2023. We have not yet decided on the format of such a regulatory interaction but we could seek advice through various formal or informal interactions with regulatory agencies or we could choose to submit a New Drug Application (NDA) if we believe that is warranted from the results of our ongoing post-hoc analyses.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:14.15pt">Continue advancing Phase 3 clinical studies of taldefgrobep alfa in SMA&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Company expects to enroll approximately 180 patients in the study.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:14.15pt">Continue advancing early discovery portfolio across multiple neuroscience and immunoscience indications&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Company's preclinical pipeline includes molecular degraders of extracellular proteins, CD38 targeting antibody recruiting molecules (ARMs), TRP channels, TDP-43 targeting small molecules, and other undisclosed targets, including those with disease-modifying potential.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;padding-left:14.15pt">Continue pursuing formulation development work with BHVN-5500 for use in combination studies with Kv7 platform&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Company is developing BHV-5500 (lanicemine), a low-trapping NMDA receptor antagonist. One potential target indication includes Complex Regional Pain Syndrome. Other disorders of interest include post-herpetic neuralgia and diabetic peripheral neuralgia. Current work is focused on formulation development.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;text-decoration:underline">Capital Position&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Cash as of September 30, 2022 was $50.7 million, excluding $0.8 million of restricted cash, compared to $76.1 million as of December 31, 2021. On October 3, 2022, in connection with the closing of the acquisition of Biohaven Pharmaceutical Holding Company Ltd. by Pfizer, Biohaven Ltd. launched with a cash balance of approximately $257.8 million. On October 25, 2022, the Company closed its previously announced public offering, which resulted in net proceeds to the Company of approximately $282.8 million.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Third Quarter 2022 Financial Highlights&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Research and Development (&#34;R&#38;D&#34;) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> R&#38;D expenses, including non-cash share-based compensation costs, were $52.8 million for the three months ended September 30, 2022, compared to $47.0 million for the three months ended September 30, 2021. The increase of $5.9 million was primarily due to increased expenses relating to our clinical programs partially offset by decreases in our program expenses for verdiperstat. Non-cash share-based compensation expense was $9.7 million for the three months ended September 30, 2022, a decrease of $0.5 million as compared to the same period in 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">General and Administrative (&#34;G&#38;A&#34;) Expenses&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">G&#38;A expenses, including non-cash share-based compensation costs, were $14.8 million for the three months ended September 30, 2022, compared to $8.5 million for the three months ended September 30, 2021. The increase of $6.3 million was primarily due to increased expenses related to accounting, legal and other professional fees associated with the Pfizer acquisition and spin-off of Biohaven Ltd. as an independent, publicly traded company. Non-cash share-based compensation expense was $7.3 million for the three months ended September 30, 2022, an increase of $2.1 million as compared to the same period in 2021. </font></div><div style="margin-top:3pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Net Loss&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> Biohaven reported a net loss for the three months ended September 30, 2022, of $68.9 million, or $1.75 per share, compared to $54.4 million, or $1.38 per share, for the same period in 2021. Non-GAAP adjusted net loss for the three months ended September 30, 2022 was $49.2 million, or $1.25 per share, compared to $39.0 million, or $0.99 per share for the same period in 2021. These non-GAAP adjusted net loss and non-GAAP adjusted net loss per share measures, more fully described below under &#8220;Non-GAAP Financial Measures,&#8221; exclude non-cash share-based compensation charges and gains or losses from equity method investment. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below. Net loss per share and Non-GAAP adjusted net loss per share were calculated based on the 39,368,042 shares of Biohaven Ltd. common stock distributed to Biohaven Pharmaceutical Holding Company Ltd. shareholders at the time of the Distribution, including common shares issued in connection with Biohaven Pharmaceutical Holding Company Ltd. stock options that were exercised on October 3, 2022 and common shares issued in connection </font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">with Biohaven Pharmaceutical Holding Company Ltd. restricted stock units that vested on October 3, 2022.  The same number of shares is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off.</font></div><div><font><br></font></div><div id="ib7678ec1110f4751ac642666e16a5cf1_10"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP), and also certain non-GAAP financial measures. In particular, Biohaven has provided non-GAAP adjusted net loss and adjusted net loss per share, adjusted to exclude the items below. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. However, Biohaven believes the presentation of non-GAAP adjusted net loss, when viewed in conjunction with GAAP results, provides investors with a more meaningful understanding of ongoing operating performance. These measures exclude (i) non-cash share-based compensation, which is substantially dependent on changes in the market price of common shares, (ii) gains or losses from equity method investment, which are non-cash and based on the financial results and valuation of another company that we did not manage or control, and (iii) transaction-related costs incurred relating to the Company's spin-off from Biohaven Pharmaceutical Holding Company Ltd., which are limited to a specific period of time and related to Biohaven Ltd. being established as a standalone public company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Biohaven believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding Biohaven's results of operations. When GAAP financial measures are viewed in conjunction with these non-GAAP financial measures, investors are provided with a more meaningful understanding of Biohaven's ongoing operating performance and are better able to compare Biohaven's performance between periods. In addition, these non-GAAP financial measures are among those indicators Biohaven uses as a basis for evaluating performance, and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this press release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Biohaven </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating neurological and neuropsychiatric diseases, including rare disorders. The company is advancing a pipeline of best-in-class therapies for diseases with little or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability&#59; glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia and myostatin inhibition for neuromuscular diseases. Biohaven's portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain and CD-38 antibody recruiting, bispecific molecules for multiple myeloma.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-looking Statements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including &#34;continue&#34;, &#34;plan&#34;, &#34;will&#34;, &#34;believe&#34;, &#34;may&#34;, &#34;expect&#34;, &#34;anticipate&#34; and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including&#58; the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials&#59; the timing of planned interactions and filings with the Food and Drug Administration&#59; the timing and outcome of expected regulatory filings&#59; complying with applicable U.S. regulatory requirements&#59; the potential commercialization of Biohaven's product candidates&#59; the potential for Biohaven's product candidates to be first in class or best in class therapies&#59; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled &#34;Risk Factors&#34; and &#34;Management's Discussion and Analysis of Financial Condition and Results of Operations&#34;. The forward-looking statements are made as of the date of this new release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib7678ec1110f4751ac642666e16a5cf1_13"></div><hr style="page-break-after:always"><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">BIOHAVEN LTD.</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">CONDENSED COMBINED STATEMENTS OF OPERATIONS</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">(Amounts in thousands, except share and per share amounts)</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">(Unaudited)</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:130%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,845&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,973&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,028&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,668&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,792&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,519&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,492&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,349&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,492&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,520&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,017&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,637)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,492)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(354,520)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168,017)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investment</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,261&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,016&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision (benefit) for income taxes</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,637)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,497)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(354,591)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163,001)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,132)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,581&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,091)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and comprehensive loss attributable to common shareholders of Biohaven Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,853)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,365)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369,172)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,910)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common shareholders of Biohaven Ltd. &#8212; basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.75)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.38)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.38)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.11)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares outstanding&#8212;basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,368,042&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,368,042&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,368,042&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,368,042&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib7678ec1110f4751ac642666e16a5cf1_16"></div><hr style="page-break-after:always"><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">BIOHAVEN LTD.</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">CONDENSED COMBINED BALANCE SHEETS</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">(Amounts in thousands)</font></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,668&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,057&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,910&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,734&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,972&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,032&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,550&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,823&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,423&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,010&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,400&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,400&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,883&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,438&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,646&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,061&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,731&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,775&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,704&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,160&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,435&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,935&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,995&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,435&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,430&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,370&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingently redeemable non-controlling interests</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment from Former Parent</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,216&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,691&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,216&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,691&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,646&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,061&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib7678ec1110f4751ac642666e16a5cf1_19"></div><hr style="page-break-after:always"><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">BIOHAVEN LTD.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">(Amounts in thousands, except share and per share amounts)</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">(Unaudited)</font></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of GAAP to Non-GAAP adjusted net loss&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,853)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,365)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369,172)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,910)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add&#58; non-cash share-based compensation expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,997&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,393&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,927&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,671&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; Gain from equity method investment</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,261)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add&#58; Transaction-related costs</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,641&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP adjusted net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,215)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,972)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285,382)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,500)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of GAAP to Non-GAAP adjusted net loss per share &#8212; basic and diluted&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP net loss per share attributable to Biohaven Ltd. &#8212; basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.75)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.38)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.38)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.11)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add&#58; non-cash share-based compensation expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.39&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.98&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.34&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; Gain from equity method investment</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add&#58; Transaction-related costs</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP adjusted net loss per share attributable to Biohaven  Ltd. &#8212; basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.25)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.99)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.25)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.91)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ib7678ec1110f4751ac642666e16a5cf1_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">MoDEs is a trademark of Biohaven Therapeutics Ltd.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor Contact&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Jennifer Porcelli</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Vice President, Investor Relations</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">jennifer.porcelli&#64;biohavenpharma.com</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">+1 (201) 248-0741</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media Contact&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Mike Beyer, Media Relations Counselor</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Sam Brown Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">mikebeyer&#64;sambrown.com</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">+1 (312) 961-2502</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>bhvn-20221109.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:21e66218-f164-470d-965c-dd4feffa9b8b,g:5b8cb720-4ac7-485e-ac76-aba17a964af5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bhvn="http://www.biohavenpharma.com/20221109" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biohavenpharma.com/20221109">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhvn-20221109_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhvn-20221109_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.biohavenpharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>bhvn-20221109_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:21e66218-f164-470d-965c-dd4feffa9b8b,g:5b8cb720-4ac7-485e-ac76-aba17a964af5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityAddressAddressLine1_1bc66b80-9909-4217-899b-0ea737dd7117_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_3d5b49aa-de1f-47ca-8114-f3748739f621_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_a04fec47-8851-4653-b9b6-09209ea8f87b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_38b8ad00-83d1-4458-9d39-6824f02d6aab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8fffdeea-eda2-4156-8f67-26ce769c089a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_9d93b392-ba81-46af-a21b-58db72cbe13c_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e5b1e82a-919a-4118-be8e-6bbdbbd1f57e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_c72a93e5-06d7-48e8-95f6-2856a6735015_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5cbbef44-4ef1-45d5-958e-1ca7984c29b4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_65b726d5-fcf6-4a09-bd51-58a0b9b89510_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7eb07f8f-4ecf-42eb-9247-ba4151c58c0d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_1f4b5bbf-b64f-4f59-8ed1-8255a8918140_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_db42fc03-2b6f-42f0-824e-8a3a6bf08b6c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_18e4f51c-563a-4ab3-9e42-0780363cf5d2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_baa41aa9-caae-47af-98f3-a755f4e65541_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_879cf2e3-11f7-4638-b503-3dc9ec6ff60d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_47a6b55f-02da-420a-9b94-68b7817f3c68_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3a815e86-0b5e-4b95-a5cc-c3ffbfa12844_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_d7eb811c-27e9-47d6-86bb-beba088465d0_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_54c13c92-5ac3-4d9d-a531-6b042f3e8cb8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8bb9aee9-e86c-4ee9-8b1e-ad1914f61fa2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c65a6dd5-1485-44d5-92a2-588a8cad0f22_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_06e69bb2-ee39-4047-aea8-fccc11e99d21_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>bhvn-20221109_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:21e66218-f164-470d-965c-dd4feffa9b8b,g:5b8cb720-4ac7-485e-ac76-aba17a964af5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/Cover" xlink:type="simple" xlink:href="bhvn-20221109.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.biohavenpharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4cba82a8-4042-42e2-a23d-6a51f0520b07" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_DocumentType_4cba82a8-4042-42e2-a23d-6a51f0520b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6f5fc3d6-df4e-4c36-b4d0-c44aecf66566" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_EntityRegistrantName_6f5fc3d6-df4e-4c36-b4d0-c44aecf66566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_90883573-bd89-4a18-9a6d-1b1515ff8645" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_DocumentPeriodEndDate_90883573-bd89-4a18-9a6d-1b1515ff8645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ce916ef1-af5a-41ec-ab11-75bfde1c4f06" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ce916ef1-af5a-41ec-ab11-75bfde1c4f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_03bd2175-adb6-4547-a2b0-18de655e43a8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_EntityFileNumber_03bd2175-adb6-4547-a2b0-18de655e43a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ab0ef91c-5404-4b56-8da6-7ffe009fd859" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_EntityAddressAddressLine1_ab0ef91c-5404-4b56-8da6-7ffe009fd859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_1c2be059-c9e6-4141-8a0d-a55620b67ebb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_EntityAddressAddressLine2_1c2be059-c9e6-4141-8a0d-a55620b67ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cba8d040-7111-48ed-b8d4-686e50d3e757" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_EntityAddressCityOrTown_cba8d040-7111-48ed-b8d4-686e50d3e757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_138ea528-1aec-4c82-a233-763fa5f8f0c3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_EntityAddressStateOrProvince_138ea528-1aec-4c82-a233-763fa5f8f0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9eddda52-556e-4479-874f-847c3250baac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_EntityAddressPostalZipCode_9eddda52-556e-4479-874f-847c3250baac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_43e4c409-5fa7-4eed-bfe8-9e9727017d9b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_CityAreaCode_43e4c409-5fa7-4eed-bfe8-9e9727017d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_757c09d1-8f20-4668-8b22-2c804002ab9d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_LocalPhoneNumber_757c09d1-8f20-4668-8b22-2c804002ab9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_5052bec2-17f7-4d78-97bf-6d3c9d02b539" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_WrittenCommunications_5052bec2-17f7-4d78-97bf-6d3c9d02b539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_2ea6ada4-bc42-4605-962d-af68ae07d33c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_SolicitingMaterial_2ea6ada4-bc42-4605-962d-af68ae07d33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_e4842214-b09e-4417-9bf4-83cf9c5e9cdb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_PreCommencementTenderOffer_e4842214-b09e-4417-9bf4-83cf9c5e9cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_5d5ffe36-92b4-4bff-8137-5e337b5b4153" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_5d5ffe36-92b4-4bff-8137-5e337b5b4153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ab5fb8b7-bf52-41c7-9a44-5074fd1ab72c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_Security12bTitle_ab5fb8b7-bf52-41c7-9a44-5074fd1ab72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8fba0856-33d1-454e-96b4-b56960e46038" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_TradingSymbol_8fba0856-33d1-454e-96b4-b56960e46038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_01ff82fd-d8c5-4d72-a8dd-ef26767d529e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_SecurityExchangeName_01ff82fd-d8c5-4d72-a8dd-ef26767d529e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_64b0e90e-6162-446e-9bcd-4aab81285fb8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_EntityEmergingGrowthCompany_64b0e90e-6162-446e-9bcd-4aab81285fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_a9e01da0-ff8f-4044-aa6b-3d2717d48a71" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_EntityExTransitionPeriod_a9e01da0-ff8f-4044-aa6b-3d2717d48a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_946ed68c-fef6-4d0c-b5a6-42724661ced5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_EntityCentralIndexKey_946ed68c-fef6-4d0c-b5a6-42724661ced5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_383383a5-06f8-43b9-8c9c-882ccda0b276" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8cb4feac-22ad-4fc7-b665-717efcdd35ae" xlink:to="loc_dei_AmendmentFlag_383383a5-06f8-43b9-8c9c-882ccda0b276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140046217913792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Biohaven Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  09,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">D8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">c/o Biohaven Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">215 Church Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">404-0410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BHVN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001935979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>bhvn-20221109_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bhvn-20221109.xsd" xlink:type="simple"/>
    <context id="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001935979</identifier>
        </entity>
        <period>
            <startDate>2022-11-09</startDate>
            <endDate>2022-11-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV80L2ZyYWc6Y2MzYTYyOTc5MTJhNDQ2MDk2MGRmOGM3ZjMyYmMzYTAvdGFibGU6YzQ5NWI4NTg1ZWY1NDVmMzhmYzdkYmUzZmMzMmU1ODAvdGFibGVyYW5nZTpjNDk1Yjg1ODVlZjU0NWYzOGZjN2RiZTNmYzMyZTU4MF8wLTEtMS0xLTIyNzIzNA_625b1c92-ae7d-49d6-a061-6ab5d65f5727">0001935979</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV80L2ZyYWc6Y2MzYTYyOTc5MTJhNDQ2MDk2MGRmOGM3ZjMyYmMzYTAvdGFibGU6YzQ5NWI4NTg1ZWY1NDVmMzhmYzdkYmUzZmMzMmU1ODAvdGFibGVyYW5nZTpjNDk1Yjg1ODVlZjU0NWYzOGZjN2RiZTNmYzMyZTU4MF8xLTEtMS0xLTIyNzIzNA_2431fe87-b528-4457-bae1-08557a7bdba3">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzY0_069aea85-fcee-4ba8-814d-ee0a28680d5c">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8yMjE_f79aa8f5-bef9-43db-b019-937a7c2df2c1">2022-11-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzY1_295b862d-421f-44a6-9e8a-d959d2a99a79">Biohaven Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGFibGU6OWIwNTNlZjAzNDI0NGJlOTk2MzMwOGQ3MDU5MWMzMjcvdGFibGVyYW5nZTo5YjA1M2VmMDM0MjQ0YmU5OTYzMzA4ZDcwNTkxYzMyN18wLTAtMS0xLTIyNzIzNA_b8d078e8-0603-4e10-a4f5-087fb4dbead1">D8</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGFibGU6OWIwNTNlZjAzNDI0NGJlOTk2MzMwOGQ3MDU5MWMzMjcvdGFibGVyYW5nZTo5YjA1M2VmMDM0MjQ0YmU5OTYzMzA4ZDcwNTkxYzMyN18wLTEtMS0xLTIyNzIzNA_d44b040e-b78a-48cc-aa95-d95c2cb21561">001-41477</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzU3_a0854a5c-fd97-4311-a985-fd8e9372c979">c/o Biohaven Pharmaceuticals, Inc.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzYx_2597c8f8-71f0-4ec2-865c-3ce26cabe7fa">215 Church Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzU4_70c400a7-b02e-4093-b3ae-315d2c078e5d">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzU5_330e3c20-815d-4da6-b2fd-914fb074b333">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzU0_c99c2a21-d9d2-4b6a-b669-13990c1d4adb">06510</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzY2_e55bb340-b8b6-4e2e-b7e4-c7ecb5c30c48">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzY3_9322b401-a552-4a99-b17a-ec6c877b1104">404-0410</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzYy_2dde2e71-5926-48d4-bf07-630b42284f44">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzU1_dd3b3028-33b9-40b1-b637-01b98052c6b4">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzU2_f71c8795-3b66-47f9-a5b9-7a1883ee458a">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzYw_4bbeb105-4d72-4da4-bd31-90239938d8df">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGFibGU6N2FiMzljMWExMzY2NGE5OGIxM2Y2NTMyYjM4ZDg0ODYvdGFibGVyYW5nZTo3YWIzOWMxYTEzNjY0YTk4YjEzZjY1MzJiMzhkODQ4Nl8xLTAtMS0xLTIyNzIzNA_f0d8adcc-254d-44ce-a008-e73a9d58f450">Common Shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGFibGU6N2FiMzljMWExMzY2NGE5OGIxM2Y2NTMyYjM4ZDg0ODYvdGFibGVyYW5nZTo3YWIzOWMxYTEzNjY0YTk4YjEzZjY1MzJiMzhkODQ4Nl8xLTEtMS0xLTIyNzIzNA_85ec11f3-7de2-4dd5-a24c-d6a84a3be816">BHVN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGFibGU6N2FiMzljMWExMzY2NGE5OGIxM2Y2NTMyYjM4ZDg0ODYvdGFibGVyYW5nZTo3YWIzOWMxYTEzNjY0YTk4YjEzZjY1MzJiMzhkODQ4Nl8xLTItMS0xLTIyNzIzNA_b2e8f358-b449-4c8b-a31d-3b1539fcc3fa">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xNzYz_a106accc-6148-4918-a033-10dd42cf8175">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109"
      id="id3VybDovL2RvY3MudjEvZG9jOmY5ZjY1NWIzZDg0OTQyZmJhMWZjNDA3NmQ4YTNlMTdhL3NlYzpmOWY2NTViM2Q4NDk0MmZiYTFmYzQwNzZkOGEzZTE3YV8xL2ZyYWc6MDcwMjA4OGRhNzNlNDdiZjg1YjFhMWRhMDg0ZTczNzEvdGV4dHJlZ2lvbjowNzAyMDg4ZGE3M2U0N2JmODViMWExZGEwODRlNzM3MV8xMDk5NTExNjI5NTg0_d25d9b8b-6dee-41cf-a2c9-863e7eb6b18e">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "R@&E5H7 $5DX$   4$0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)V8:X_B-A2&_XJ52E4KS4PNW*> ! S3&>TLBP:ZJ[;J!Y,88FUBIX[#Y=_W
M.$!"M>&$W2\D3G)>GMCGO+;3WTGU-0T9TV0?1R(=6*'6R:-MIW[(8IH^R(0)
MN+.6*J8:FFICIXEB-,B#XLCV'*=MQY0+:]C/K\W5L"\S'7'!YHJD61Q3=1BS
M2.X&EFN=+[SS3:C-!7O83^B&+9C^(YDK:-F%2L!C)E(N!5%L/;!&[N/8:YF
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MAE9.$"[J[]^@S66J:43^XLG5XJU1=-HMU\'8RLG!Q>T]'\,1+(JNH^ "GM/
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ME5BX6AU6:?/>31N!"92D K]_A6K<DP^LNJMP*0>6CKU&J]?I862EW7NX2X_
M)H+<*IXCNJGD^4&;MR_VN.9[P4=JDB4E$5N#D//0 5UUW((?&UHF^;9W)35L
MHO/3D%'P+?, W%]+J<\-LY,N/H0,_P-02P,$%     @ LH!I59^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
MLH!I59>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC '
MT"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2
M:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=
MI3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8
M%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+
M P04    " "R@&E5JL0B%C,!   B @  #P   'AL+W=O<FMB;V]K+GAM;(U1
MT6[", S\E2H?L!:T(0U17D#;D*8-C8GWT+K4(HDKQX6-KY_;JAK27O:4W-FZ
MW%T6%^+3@>B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:
M9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7<P.6/$ SJ4[]ST=P<F\1C0XQ7*
MW&0FB35=7HCQ2D&LVQ5,SN5F,@SVP(+%'WK7F?RTA]@S8@\?5HWD9I:I8(4<
MI=_H]:UZ/(,N#Z@5>D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"F
MHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508
MH'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @
MLH!I520>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ LH!I50=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "R@&E59D5[
MUN\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " "R@&E5F5R<(Q &  "<)P  $P              @ '- 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +* :56A< 163@0  !01
M   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " "R@&E5GZ ;\+$"  #B#   #0              @ &2#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +* :567BKL<P    !,"   +
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4!08     "0 ) #X"  #F$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="bhvn-20221109.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biohavenpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0547-EntityTaxIdentificationNumber-Missing] Submission type 8-K should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. bhvn-20221109.htm </Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="bhvn-20221109.htm">bhvn-20221109.htm</File>
    <File>a2022q3bhvnltdearningsprex.htm</File>
    <File>bhvn-20221109.xsd</File>
    <File>bhvn-20221109_lab.xml</File>
    <File>bhvn-20221109_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bhvn-20221109.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "bhvn-20221109.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bhvn-20221109_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bhvn-20221109_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bhvn-20221109.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "bhvn",
   "nsuri": "http://www.biohavenpharma.com/20221109",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhvn-20221109.htm",
      "contextRef": "i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://www.biohavenpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhvn-20221109.htm",
      "contextRef": "i6628efb0cdbb4d62843d0035f2f989b9_D20221109-20221109",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biohavenpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001935979-22-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001935979-22-000009-xbrl.zip
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M@9J!I)NO]2(?B.!,_NLY8O$5ET< B;_@:QSH%_N)L0X3?> .-/3%B-.R_2%
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MC#481!;/R(N#$O1I+4XWEH$)5>]'F585[>GRJR0N.#4<?4>!PUTWJJ6#-;E
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MSTVR4NE@,2J.3Q_T+1*XWZ<_8[I]^K/&D.FO1GR:_JABD-/?)$EPJ@8TK5&
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MT>QL&11?[%!K^T/$RT>[/\54WD7)W4[!;$2)??""[")KMU)*K\+9M^O_R-^
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M"\W0[IX=EOG0\^PI_&\8CIQ/_Q]02P,$%     @ LH!I58SH6OWG%   F8(
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MA] W87X6T(.GY"_:D-?/E<$;<#^,!@,_$34 2&@.E*F.GPW+>OL8U0;#()H
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M>LH'B!05DDG,ZO]MGHR"5%:=MT _SP[;0,NB#W,%?!B!01 -Q<W'9ZL89T0
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M[=U]T;UT_X5QM/<_4$L! A0#%     @ LH!I5<56GP^:+@  8B\" !X
M         ( !     &$R,#(R<3-B:'9N;'1D96%R;FEN9W-P<F5X+FAT;5!+
M 0(4 Q0    ( +* :56,Z%K]YQ0  )F"   1              "  =8N  !B
M:'9N+3(P,C(Q,3 Y+FAT;5!+ 0(4 Q0    ( +* :57,0&"<< (  (8'   1
M              "  >Q#  !B:'9N+3(P,C(Q,3 Y+GAS9%!+ 0(4 Q0    (
M +* :56J< JU>PH  #]A   5              "  8M&  !B:'9N+3(P,C(Q
M,3 Y7VQA8BYX;6Q02P$"% ,4    " "R@&E5%0 L-=X&  !3,P  %0
M        @ $Y40  8FAV;BTR,#(R,3$P.5]P<F4N>&UL4$L%!@     %  4
*4 $  $I8      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
